Weal and woe of interleukin-18 in the T cell therapy of cancer
Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a do...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/1/e010545.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527935592300544 |
|---|---|
| author | Christoph Kessel Hinrich Abken Claudia Rossig |
| author_facet | Christoph Kessel Hinrich Abken Claudia Rossig |
| author_sort | Christoph Kessel |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a double-edged sword in CAR T cell therapies. |
| format | Article |
| id | doaj-art-ddca0257b30c436aa70363311d82d38c |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-ddca0257b30c436aa70363311d82d38c2025-01-15T04:50:13ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-01-0113110.1136/jitc-2024-010545Weal and woe of interleukin-18 in the T cell therapy of cancerChristoph Kessel0Hinrich Abken1Claudia Rossig2Translational Inflammation Research, Department of Pediatric Rheumatology & Immunology, University of Münster Faculty of Medicine, Munster, GermanyDivision Genetic Immunotherapy, Leibniz Institute for Immunotherapy, Regensburg, GermanyDepartment of Pediatric Hematology and Oncology, University Children`s Hospital Muenster, Munster, GermanyChimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a double-edged sword in CAR T cell therapies.https://jitc.bmj.com/content/13/1/e010545.full |
| spellingShingle | Christoph Kessel Hinrich Abken Claudia Rossig Weal and woe of interleukin-18 in the T cell therapy of cancer Journal for ImmunoTherapy of Cancer |
| title | Weal and woe of interleukin-18 in the T cell therapy of cancer |
| title_full | Weal and woe of interleukin-18 in the T cell therapy of cancer |
| title_fullStr | Weal and woe of interleukin-18 in the T cell therapy of cancer |
| title_full_unstemmed | Weal and woe of interleukin-18 in the T cell therapy of cancer |
| title_short | Weal and woe of interleukin-18 in the T cell therapy of cancer |
| title_sort | weal and woe of interleukin 18 in the t cell therapy of cancer |
| url | https://jitc.bmj.com/content/13/1/e010545.full |
| work_keys_str_mv | AT christophkessel wealandwoeofinterleukin18inthetcelltherapyofcancer AT hinrichabken wealandwoeofinterleukin18inthetcelltherapyofcancer AT claudiarossig wealandwoeofinterleukin18inthetcelltherapyofcancer |